MAPT and Alzheimer disease: On a molecular level, patients who develop AD symptoms accumulate beta-amyloid (Aβ) aggregates and tau neurofibrillary tangles (NFTs) (Selkoe, 2001; Aisen et al., 2017; Porsteinsson et al., 2021).